

Promacta® (eltrombopag) - First-time generic

- On May 14, 2025, <u>Camber launched</u> an <u>AB-rated</u> generic version of Novartis' <u>Promacta</u> (eltrombopag) tablets and packets for oral suspension.
- Promacta is approved for the following indications:
 - Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
 - Treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy
 - In combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
 - Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
- Promacta carries a boxed warning for risk for hepatic decompensation in patients with chronic hepatitis C and risk of hepatotoxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.